Bioalliance PharmaAct Nom. Cat-P AktieWKN: A0HMXA / ISIN: FR0010095596

3,96EUR
-0,05EUR
-1,25%
09:08:48
29,90DKK
±0,00DKK
±0,00%
10:16:00
KAUFEN
VERKAUFEN

Bioalliance PharmaAct Nom. Cat-P News

31.07.17
Onxeo Divests Two Non-Core Products in Oral Pathologies to Vectans Pharma (Businesswire)
28.07.17
Onxeo Reports First-Half 2017 Results and Business Update (Businesswire)
06.07.17
Summary of Onxeo’s Liquidity Contract With CM-CIC SECURITIES (Businesswire)
20.06.17
Onxeo successfully raises €15 Million with US and European investors (Businesswire)
19.06.17
Onxeo Launches a Capital Increase by Means of an Accelerated Book-Build Offering (Businesswire)
23.05.17
Onxeo Announces 10th Positive DSMB Recommendation to Continue Livatag® ReLive Phase III Trial in HCC (Businesswire)
10.05.17
Onxeo Announces Allowance of U.S. Patent for Livatag® in Hepatocellular Carcinoma (Businesswire)
10.05.17
Clinigen and Onxeo Initiate Managed Access Programme for Belinostat in Europe for Patients with Peripheral T-cell Lymphoma (PTCL) (Businesswire)
26.04.17
Onxeo: Annual General Meeting of April 26, 2017 (Businesswire)
26.04.17
Onxeo: Q1 2017 Financial Information and Business Update (Businesswire)
25.04.17
Onxeo S.A. : Publication of 2016 Registration Document (Businesswire)
24.04.17
Clinigen and Onxeo initiate Managed Access programme for belinostat in Europe for patients with peripheral T-cell lymphoma (PTCL) (Businesswire)
20.04.17
Onxeo Receives the EnterNext Tech 40 Label (Businesswire)
05.04.17
Onxeo: Combined General Meeting on April 26, 2017 (Businesswire)
21.03.17
Onxeo to Present Data Supporting Three Key Orphan Oncology Assets at AACR Annual Meeting (Businesswire)
07.03.17
Onxeo: Full-year 2016 Results and Outlook for 2017 (Businesswire)
01.03.17
Onxeo Appoints Seasoned Executives to Accelerate Preclinical and Clinical Development (Businesswire)
13.02.17
Onxeo Receives USPTO Notice of Allowance for a new AsiDNATM-Related Patent, Expanding Its IP Protection in the U.S. (Businesswire)
08.02.17
Onxeo: Information on ReLive Trial Design and Role of its Data Safety and Monitoring Board (Businesswire)
31.01.17
Radiotherapy, Immunotherapy and DNA Repair Inhibitors: a Winning Combination towards the Oncology of the Future (Businesswire)
24.01.17
Onxeo Completes Enrollment in Phase III Study of Livatag® for the Treatment of Hepatocellular Carcinoma (Businesswire)
17.01.17
Onxeo: Disclosure of the Total Number of Voting Rights and Shares Composing the Share Capital (Businesswire)
09.01.17
Summary of Onxeo’s Liquidity Contract With CIC (Businesswire)
06.01.17
EQS-News: Bioalliance PharmaAct Nom. Cat-P (EQS Group)
08.12.16
Onxeo: The French Academy of Sciences Awards the Guy Lazorthes Prize to Doctor Marie Dutreix for Her Innovative Research on the Dbait Technology (Businesswire)
07.12.16
Onxeo Announces Its Financial Calendar for 2017 (Businesswire)
29.11.16
Onxeo Strengthens AsiDNATM Patent Protection in Europe (Businesswire)
28.11.16
Onxeo to Participate in the Guggenheim Securities 4th Annual Boston Healthcare Conference (Businesswire)
21.11.16
Onxeo Announces 9th Positive DSMB Recommendation to Continue Livatag® ReLive Phase III Trial in HCC (Businesswire)
04.11.16
Onxeo Announces Promising Results from Preclinical Studies of Livatag® in Pancreatic Cancer (Businesswire)
27.10.16
Onxeo Announces Promising Results from Preclinical Study of Beleodaq® Combination with Checkpoint Inhibitors (Businesswire)
25.10.16
Onxeo Reports Third Quarter 2016 Financial Information and Provides Business Update (Businesswire)
10.10.16
Onxeo to Present at the 15th Annual BIO Investor Forum in San Francisco (Businesswire)
29.09.16
Onxeo Launches Capital Increase (Businesswire)
12.09.16
Onxeo Announces First Outcomes of Livatag® Preclinical Plan (Businesswire)
07.09.16
Onxeo to Present at the 18th Annual Rodman and Renshaw Global Investment Conference in New York (Businesswire)
07.09.16
Onxeo S.A.: Combination of AsiDNA and PARP Inhibitors Demonstrates Synergistic Effect, Bypasses Genetic Restriction (Businesswire)
28.07.16
Onxeo Reports First-Half 2016 Business Update and Consolidated Financials (Businesswire)
27.07.16
Onxeo Signs Exclusive License Agreement with Pint Pharma for the Commercialization of Beleodaq® in PTCL in South America (Businesswire)
07.07.16
Onxeo collaborates with the Royal College of Surgeons in Ireland for research program on Beleodaq® derivatives (Businesswire)
Seite: 12345

Bioalliance PharmaAct Nom. Cat-P News

Bioalliance PharmaAct Nom. Cat-P News: auf dieser Seite finden Sie alle Bioalliance PharmaAct Nom. Cat-P News und Nachrichten zur Bioalliance PharmaAct Nom. Cat-P Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Bioalliance PharmaAct Nom. Cat-P News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Bioalliance PharmaAct Nom. Cat-P News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.

Meistgelesene Bioalliance PharmaAct Nom. Cat-P News

Keine Nachrichten gefunden.
Weitere Bioalliance PharmaAct Nom. Cat-P News

Bioalliance PharmaAct Nom. Cat-P Peer Group News

Keine Nachrichten gefunden.

Online Brokerage über finanzen.net

Das Beste aus zwei Welten: Handeln Sie für nur 5 Euro Orderprovision* pro Trade unmittelbar aus der Informationswelt von finanzen.net!
Zur klassischen Ansicht wechseln

Willkommen bei finanzen.net Brokerage

Handeln Sie für nur 5 Euro Orderprovision* pro Trade unmittelbar aus finanzen.net!

Weitere Informationen finden Sie hier.

Jetzt informieren und Depot eröffnen


Sie haben bereits ein Depot? Dann verknüpfen Sie es jetzt mit Ihrem finanzen.net-Account!

Jetzt verknüpfen

Top News
Aktie im Fokus
10:10 Uhr
Sixt-Aktie notiert am SDAX-Ende
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Goldpreis
Meistgesucht
Deutsche Bank AG514000
Daimler AG710000
Volkswagen (VW) AG Vz.766403
Scout24 AGA12DM8
BMW AG519000
Apple Inc.865985
E.ON SEENAG99
Allianz840400
Air Berlin plcAB1000
CommerzbankCBK100
Siemens AG723610
TeslaA1CX3T
EVOTEC AG566480
Nordex AGA0D655
Amazon906866